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Recent EU legislation has introduced endocrine disrupting properties as a hazard-based ‘‘cut-off’’ criterion
for the approval of active substances as pesticides and biocides. Currently, no speciﬁc science-based
approach for the assessment of substances with endocrine disrupting properties has been agreed upon,
although this new legislation provides interim criteria based on classiﬁcation and labelling.
Different proposals for decision making on potential endocrine disrupting properties in human health
risk assessment have been developed by the German Federal Institute for Risk Assessment (BfR) and other
regulatory bodies. All these frameworks, although differing with regard to hazard characterisation, include
a toxicological assessment of adversity of the effects, the evaluation of underlying modes/mechanisms of
action in animals and considerations concerning the relevance of effects to humans.
Three options for regulatory decisionmakingwere tested upon 39 pesticides for their applicability and to
analyze their potential impact on the regulatory status of active substances that are currently approved for
use in Europe: Option 1, based purely on hazard identiﬁcation (adversity, mode of action, and the plausi-
bility that both are related); Option 2, based on hazard identiﬁcation and additional elements of hazard
characterisation (severity and potency); Option 3, based on the interim criteria laid down in the recent
EU pesticides legislation. Additionally, the data analysed in this study were used to address the questions,
which parts of the endocrine systemwere affected, which studies were themost sensitive and whether no
observed adverse effect levels were observed for substance with ED properties.
The results of this exercise represent preliminary categorisations andmust not be used as a basis for deﬁn-
itive regulatory decisions. They demonstrate that a combination of criteria for hazard identiﬁcation with
additional criteria of hazard characterisation allows prioritising and differentiating between substanceswith
regard to their regulatory concern. It is proposed to integrate these elements into a decisionmatrix to beused
withinaweightof evidenceapproach for the toxicologicalcategorisationof relevantendocrinedisruptors and
to consider all parts of the endocrine system for regulatory decision making on endocrine disruption.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction Accordingly, substances with endocrine disrupting properties thatRecent EU legislation has introduced endocrine disrupting
properties as one of a number of new hazard-based ‘‘cut-off’’
criteria for the approval of active substances in plant protection
products (Reg. (EC) No 1107/2009; European Council, 2009).may cause adverse effects in humans may only be approved if
exposure is negligible.
However, no speciﬁc science-based criteria for the assessment
of substances with endocrine disrupting properties have been
agreed upon so far. For pesticides, the EU Commission is requiredty); BfR,
ulations
ity; EPA,
ls); HPA,
hemicals
sition of
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for the determination of endocrine disrupting properties in the
near future. Pending adoption of speciﬁc scientiﬁc criteria, the
new plant protection products regulation provides interim criteria
for identiﬁcation of some substances with endocrine disrupting
properties for non-approval, based on classiﬁcation and labelling:
‘‘. . .substances that are or have to be classiﬁed, in accordance with
the provisions of Regulation (EC) No 1272/2008, as carcinogenic cate-
gory 2 and toxic for reproduction category 2, shall be considered as
having endocrine-disrupting properties. . . .substances such as those
that are or have to be classiﬁed, in accordance with the provisions of
Regulation (EC) No 1272/2008, as toxic for reproduction category 2
and which have toxic effects on the endocrine organs, may be consid-
ered as having endocrine-disrupting properties’’ (Reg. (EC) No 1107/
2009; European Council, 2009). Similar provisions for a regulatory
‘‘cut-off’’, based on endocrine disrupting properties and including
interim criteria for the determination of endocrine disrupting
properties are also provided in the new EU biocides regulation
528/2012 (European Parliament and Council, 2012).
Assessment and regulation of substances with potential
endocrine disrupting properties is associated with a number of
challenges. The endocrine system is extremely complex and is
involved in virtually all functions of the vertebrate organism
(WHO/IPCS, 2002; WHO/UNEP, 2013). Consequently, any effect
observed in a toxicity study might theoretically be linked to an
alteration of function of the endocrine system. Since administra-
tion of high doses of test chemicals in pre-approval animal studies
is mandatory according to internationally harmonised test guide-
lines and data requirements under regulatory frameworks, the
majority of active substances in plant protection or biocidal prod-
ucts have been found to show at least some signiﬁcant toxicity.
Currently, the mechanism or mode of action leading to a toxic
effect is often not clear and judgement whether it is endocrine
mediated or not is difﬁcult.
A related challenge is that the process of endocrine disruption
does not correspond to a single endpoint per se. Endocrine disrup-
tion includes a variety of different mechanisms of toxicity that may
affect different individual endpoints. Moreover, even though in the
past decade several assays have been developed and validated to
detect substance-induced effects caused by interference with the
hypothalamic-pituitary-gonadal (HPG) axis, there are many other
components of the endocrine system, for which at present no or
only insufﬁciently validated speciﬁc mechanistic assays are avail-
able. In fact, if endocrine disruption is discussed in the public,
the focus is very often on substances potentially affecting fertility
and reproduction via interaction with steroid hormone systems
such as the estrogen or androgen systems. Sometimes additionally
effects on the thyroid hormone system are discussed whereas
other parts of the endocrine system like the adrenal gland or the
pancreas are seldomly taken into consideration.
Although substances with endocrine disrupting properties have
been addressed in different sections of EU chemicals regulation
(e.g. plant protection products regulation, biocides regulation,
REACH), current data requirements and options for management
decisions differ signiﬁcantly between regulations. While data
requirements under the recent EU pesticides regulation cover an
extensive set of toxicity studies in at least four animal species, the
scope of the data package for chemicals under REACH (Regulation
EC No. 1907/2006) depends on the production volume and may
notbe as comprehensive as for pesticides (Beronius et al., 2009). Fur-
thermore, the downstream regulatory consequences for substances
with endocrine disrupting properties currently appear to differ
between regulations. Active substances, safeners or synergists with
endocrine disrupting properties to be used in plant protection are
not to be authorised even if risk assessment demonstrates that there
is no risk associated because of very limited exposure. This ‘‘cut-off’’is to be applied ‘‘unless the exposure of humans to that active sub-
stance, safener or synergist in a plant protectionproduct, under real-
istic proposed conditions of use, is negligible, that is, when the
product is used in closed systems or in other conditions excluding
contact with humans and where its residues in food and feed do
not exceed the default value set in accordancewith point (b) of Arti-
cle 18(1) of Regulation (EC)No 396/2005’’ (European Council, 2009).
By contrast, chemicals under REACH (Reg. (EC) No 1907/2006) that
have endocrine disrupting properties for which there is scientiﬁc
evidence of probable serious effects to human health may be nomi-
nated for a candidate list in accordancewith Article 57f. Thatmeans
that these substances should become subject to an authorisation
procedure and may not be placed on the market unless they have
been authorised (European Council, 2006).
Although conclusions on endocrine disruptors in a regulatory
context are required under the European regulations on plant pro-
tection products and also on biocides (European Parliament and
Council, 2012) the lack of agreed criteria makes implementation of
thesepieces of legislationdifﬁcult. For toxicological hazards like car-
cinogenicity, reproductive toxicity or speciﬁc target organ toxicity,
criteria for categorisation have already been established and inter-
nationally agreed upon in the Globally Harmonized System of Clas-
siﬁcation and Labelling of Chemicals (GHS)whichwas implemented
into European legislation byRegulation (EC)No1272/2008 (CLP reg-
ulation) (EuropeanCouncil, 2008). However, theCLP regulationdoes
not deﬁne a speciﬁc hazard class of endocrine disruptors. In this
context it has been argued that endocrine disruption is based on a
variety ofmechanisms of action thatmay lead to adverse health out-
comes like cancer, reproductive disease or speciﬁc target organ tox-
icity, but does not represent in itself a single endpoint that would
require classiﬁcation or labelling (ECETOC, 2009). Furthermore,
any substance that causes cancer or effects on reproduction and
development like reduced fertility or malformations by an endo-
crinemode of actionwould be expected to be classiﬁed accordingly.
However, considerationof speciﬁc toxicityonendocrine-related tar-
get organs also seems to be important in assessment of endocrine
disruptors. If the regulatory ‘‘cut-off’’ was based alone on current
classiﬁcation for carcinogenicity (C) and/or reproductive toxicity
(R), a substancewith speciﬁc toxic effects on the adrenals or thepan-
creasmight not be banned as an endocrine disruptor, in contrast to a
substance known or presumed to cause reproductive toxicity by an
endocrine-related mechanism in humans.
Recently, different sets of criteria have been discussed, address-
ing the challenges mentioned above (Bars et al., 2011; Marx-
Stoelting et al., 2011). Governmental agencies such as the Danish
EPA (Danish Ministry of the Environment, 2011), French ANSES
(ANSES, 2012), British CRD/German BfR (BfR and CRD, 2011) and
non-governmental organisations like ECETOC (2009) or
Chemtrust (2011) have made proposals available on their websites.
A number of these proposals have been summarised in a EU report
(Kortenkamp et al., 2012). Scientiﬁc issues on the identiﬁcation
and characterisation of endocrine disruptors have also been dis-
cussed by expert panels at the European level and results of these
discussions have been summarised in recent reports (EFSA
Scientiﬁc Committee, 2013; Endocrine Disrupters Expert Advisory
Group, 2013). While most of these approaches have some princi-
ples in common regarding hazard identiﬁcation, they also show
differences especially when it comes to proposals for decision
making concerning the regulatory ‘‘cut-off’’. Most proposals are
based on the WHO/IPCS deﬁnition for endocrine disruptor as
‘‘. . .an exogenous substance or mixture that alters function(s) of the
endocrine system and consequently causes adverse health effects in
an intact organism, or its progeny, or (sub)populations’’ (WHO/IPCS,
2002), and as such concentrate on adverse effects caused by a sub-
stance, taking into account the mode or mechanism of action
which has to be related to endocrine disruption. In addition, most
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and to consider relevance to humans. Signiﬁcant differences
remain in the way by which additional criteria of hazard character-
isation like speciﬁcity, severity of effects or doses at which effects
occur could be integrated into the regulatory decision.
The primary aim of this study was to evaluate different options
for hazard based regulatory decision making by applying them to
a number of active substances currently approved in plant protec-
tion products in the EU. This approach has been suggested by the
BfR in 2011 (Marx-Stoelting et al., 2011). To simulate the range of
substances encountered in regulatory practice, known ‘‘positives’’
as well as substances with unknown endocrine disrupting proper-
ties and presumed controls were included in the study. In addition
the data analysed in this study were also used to address the ques-
tions, which parts of the endocrine systemwere affected by EDmost
frequently, which studieswere themost sensitive in detection of ED
effects and whether or not no observed adverse effect levels (NOA-
ELs) were observed for substance with ED properties. Since no gold
standard for any regulatory decision on endocrine disruption exists,
this exercise cannot formally validate any set of criteria. However,
the results of this study will allow a comparison of discussed
approaches for regulatory decision making in terms of numbers of
substances sorted out, applicability of criteria and reproducibility
of decisions based on them and also whether or not criteria allow
prioritising substances for regulatory decision making.2. Materials and methods
2.1. Substance selection
Three sets of substances, 39 substances in total, were selected.
The ﬁrst set consisted of substances potentially falling under the
interim ‘‘cut-off’’ criteria for endocrine disruption set by Regulation
EC No 1107/2009, (i.e. substances classiﬁed in accordance with
Regulation EC 1272/2008 as carcinogenic category 2 and toxic for
reproduction category 2 shall be considered to have endocrine dis-
rupting properties and substances classiﬁed as toxic for reproduc-
tion category 2 and showing effects on endocrine organs may be
considered to have endocrine disrupting properties (European
Council, 2009)).
This ﬁrst set of substances was selected by a classiﬁcation-
based search in the EU pesticides database (http://ec.europa.eu/
sanco_pesticides/public/index.cfm), accessed in January 2011 and
re-accessed in July 2013. The search was limited to active
substances having been approved for pesticidal use in the EU. Fur-
thermore, it was limited to substances with a current legal classi-
ﬁcation of ‘toxic for reproduction’ category 2 and/or ‘carcinogenic’
category 2, not taking into account substances with proposed clas-
siﬁcations. In addition to the EU pesticides database, Annex VI of
Regulation EU 1272/2008 was searched for candidate pesticides
where the status of classiﬁcation and labelling was not clear and
to conﬁrm results obtained in the pesticides database by accessing
the European Substance Information System (ESIS) on http://
esis.jrc.ec.europa.eu. Table 1 lists all substances retrieved by this
strategy.
The second set (Table 2) consisted of substances selected from
Annex 1 of Directive 91/414/EEC by use of a computer-based ran-
dom generator. Substances in Annex 1 were numbered from 1 to
351 (the total number of approved active substances at the begin-
ning of the study) and the random generator was used to generate
22 integral numbers between 1 and 351. The substances selected
by this approach were chosen for analysis of potential endocrine
disrupting properties. Randomisation was considered especially
important since a selection based on classiﬁcation for reproductive
toxicity as applied to generate the ﬁrst set of substances, clearlyshows a bias for substances potentially affecting the hypotha-
lamic-pituitary-gonadal (HPG) axis of the endocrine system. For
the intended analysis of questions (such as which percentage of
all substances approved as active substances in plant protection
products might be ﬂagged for ‘‘cut-off’’ by applying the different
criteria and if endocrine targets other than the HPG system might
be affected by endocrine disruption) it was considered important
to obtain an unbiased selection of substances.
A third set of three substances (listed in Table 3) approved for
use in organic farming in the EU was selected randomly from
annex II of Regulation (EC) No 834/2007 (European Council,
2007) (as amended by Regulation (EC) No 889/2008), accessed
through the following web page: http://www.bmelv.de/
SharedDocs/Downloads/Landwirtschaft/OekologischerLandbau/
EGOekoVOAnhang2.html.2.2. Data evaluation
All available data from regulatory studies were checked for
indications of endocrine disrupting properties. As indications for
ED properties any reported pathological or histopathological
change in glands, any change in hormone levels, effects on repro-
duction or development or tumours in hormone dependent organs
were taken into account. In addition, a literature search for pub-
lished articles was performed through Pubmed (www.pub-
med.com). The substance name was entered as the primary
search term. If up to 20 results were found for the substance name,
all abstracts were checked and papers were selected for a complete
evaluation if they analysed mammalian toxicology and/or potential
endocrine effects of the substance (e.g. publications on chemical
synthesis, analytical methods or ecotoxicity were not taken into
account). If more than 20 results were obtained ‘‘‘substance name’
AND ‘toxicity’’’ or ‘‘‘substance name’ AND ‘endocrine’’’ or ‘‘‘sub-
stance name’ AND ‘hormone’’’ were entered into Pubmed. All
abstracts found by this reﬁned search strategy were then analysed
and, again, papers were selected for a complete evaluation if their
subject was mammalian toxicology and/or potential endocrine
effects.
In addition, mechanistic information and information on rele-
vance to humans was collected, if available. Since it would have
been beyond the scope of this analysis to conduct a new evaluation
of existing studies, the respective summaries and evaluations in EU
monographs, EFSA conclusions or EC scientiﬁc conclusions were
chosen as a main source for toxicological ﬁndings with the selected
compounds. Data were summarised in tabular form by taking into
account the animal species, type of study and route of exposure
(e.g. rat, 90-d, oral), the reliability of the study the adverse effects
observed and their respective dose levels.
In addition to testing the sensitivity, reproducibility and appli-
cability of the suggested regulatory options, several other points
were addressed in the evaluation. One important question was
which part(s) of the endocrine system were affected by the sub-
stances analysed in this exercise. Because of the ongoing discussion
whether to include all subsystems of the hormonal system, rather
than to focus on components and targets of the HPG axis, all effects
that could be associated with a hormonal subsystem were taken
into account. Further questions were related to the types of effect
which might lead to identiﬁcation as an endocrine disruptor (e.g.
weight changes of glands, histopathology of endocrine related
organs, changed fertility parameters, etc) and to the most sensitive
study designs for the detection of these effects (e.g. the two-gener-
ation reproductive toxicity study or a chronic or carcinogenicity
study). Additionally, it was analysed whether a NOAEL was
observed for the endocrine effects in the available toxicological
database.
Table 1
List of substances classiﬁed as ‘toxic to reproduction’ (Rep) category 2 and/or ‘carcinogenic’ (Carc) category 2, potentially falling under the preliminary cut-off criteria set by
Regulation (EC) No 1107/2009 according to the EU Pesticides database accessed under http://ec.europa.eu/sanco_pesticides/public/index.cfm?event=activesubstance. Target
organs and effects found in toxicity studies and/or leading to classiﬁcation and labelling are presented in accordance with the EU List of Endpoints as published for the individual
substances in the EFSA Journal or EFSA Scientiﬁc Reports or Review Reports of the European Commission. The 16 substances analysed by several risk assessors independently are
listed ﬁrst and are printed in bold and underlined. In addition to these 16 substances the table also contains some substances classiﬁed after January 2011 and some substances,
labelled Carc category 2, showing potential indications for endocrine disruption, which would not fall under the preliminary cut-off criteria.
Substance name Classiﬁcation (human health) Target organs (effects considered for decision on ED) Remarks
Amitrol Rep 2 (H361d), STOT RE 2 (H373) Thyroid (hormone levels, histopathology, tumours) European Commission (2001)
Bromoxynil Rep 2 (H361d), Skin sens 1 (H317), Acute
Tox 2 & 3 (H301, 330)
Malformations at maternally toxic dose levels; liver (histopathology,
weight)
European Commission
(2004a)
Chlorotoluron Carc 2 (H351), Rep 2 (H361d) Liver (enzyme induction), kidney (tumours), spleen, developmental
toxicity (resorptions, skeletal anomalies)
European Commission
(2005a)
Dimoxystrobin Rep 2 (H361d), Carc 2 (H351), Acute Tox
4 (H332)
Duodenum (tumours), thyroid (tumours), developmental toxicity
(slight microcytic hypochromic anaemia, reduced body weight gain,
reduced thymus weight, discoloured liver, cardiomegaly)
EFSA Scientiﬁc Report (2005)
46: 1-82
Epoxiconazole Carc 2 (H351), Rep 2 (H361fd) Liver (increased organ weight, clinical chemistry, chronic hepatitis),
adrenals (histopathology), ovaries, reproductive toxicity (impaired
fertility, prolonged gestation, dystocia), developmental tox.
(malformations: cleft palates in rat; higher abortion and resorption
rate)
EFSA (2008b)
Fenpropimorph Rep 2 (H361d), Acute Tox 4 (H302) Liver (weight, clinical chemistry), inhibition of cholinesterase,
developmental toxicity (malformations)
EFSA (2008c)
Ioxynil Rep 2 (H361d), Acute Tox. 3 & 4 (H301,
H331, H312), Eye Irrit 2 (H319), STOT
RE 2 (H373)
Liver (histopathology, tumours), thyroid (histopathology, tumours),
uterus (tumours), developmental toxicity (malformations at maternal
toxic dose levels, variations)
European Commission
(2004b)
Isoxaﬂutole Rep 2 (H361d) Liver (histopathology, tumours); thyroid (histopathology, tumours),
eye (ocular lesions), developmental toxicity (delayed ossiﬁcation)
European Commission
(2003c)
Linuron Rep 1B (H360Df), Carc. 2 (H351), Acute
Tox 4 (H302), STOT RE 2 (H373)
Liver, red blood cells, testes (Leydig cell tumours) reproductive toxicity
(infertility), developmental toxicity (malformations)
European Commission
(2002f)
Mancozeb Rep 2 (H361d), Skin Sens 1 (H317) Thyroid (inhibition of thyroid peroxidase, histopathology, tumours),
developmental toxicity (malformations at high dose levels, abortions,
delayed ossiﬁcation)
European Commission (2009)
Maneb Rep 2 (H361d), Acute Tox. 4 (H332),
Eye Irrit 2 (H319), Skin Sens 1 (H317)
Thyroid (inhibition of thyroid peroxidase, histopathology), liver
(histopathology, tumours), developmental toxicity (malformations at
high dose levels, resorptions, delayed ossiﬁcation)
Review Report on the Active
Substance Maneb
Metconazole Rep 2 (H361d), Acute Tox 4 (H302) Liver (histopathology, clinical chemistry), spleen (atrophy), adrenals
(histopathology) developmental toxicity (embryonic death,
postimplantation loss, malformations)
EFSA (2006)
Molinat Rep 2 (H361f), Carc 2 (H351), Acute
Tox 4 (H332, H302), STOT RE 2 (H373),
Skin Sens 1 (H317)
Testes (degenerative changes), liver (histopathology), adrenals
(histopathology), ovaries (degenerative changes), kidneys (tumours),
nervous system (degenerative changes), reproductive toxicity
(decreased fertility)
European Commission
(2003d)
Oxadiargyl Rep 1A (H360Fd), STOT RE 2 (H373) Liver (histopathology); thyroid (histopathology), developmental
toxicity (litter loss and growth retardation as a consequence of haem
synthesis inhibition at maternal toxic dose levels)
Formerly classiﬁed Rep 2,
reclassiﬁcation after Jan 2011
Tebuconazole Rep 2 (H361d), Acute Tox 4 (H302), Adrenals (histopathology), liver (histopathology), developmental
toxicity (resorptions, malformations)
EFSA (2008f)
Tepraloxydim Carc 2 (H351), Rep 2 (H361d) Liver (histopathology, tumours), bladder, thyroid, prostate
epididimydes, reproductive toxicity (decreased pup weight, delayed
eye opening), developmental toxicity (malformations)
European Commission
(2004c)
Additional substances not considered in the exercise but meanwhile also labelled R2 or C2
Cyproconazole Rep 2 (H361d), Acute Tox 4 (H302) Liver (histopathology, weight, tumours), slightly increased pre-, peri-
and postnatal mortality, malformations (cleft palate, hydrocephaly)
Classiﬁed after Jan 2011;
EFSA (2010c)
Etridiazole Carc 2 (H351), Acute Tox 3 & 4 (H302,
H312, H331)
Testes (tumours), thyroid (tumours), liver (increased organ weight,
histopatology), developmental toxicity (reduced body weight, retarded
ossiﬁcation)
C2 with tumours in endocrine
related organs EFSA (2010a)
Diuron Carc 2 (H351), STOT RE 2 (H373), Acute
Tox 4 (H302)
Mammary (tumours), bladder (urothelial tumours), blood (haemolytic
anaemia)
C2 with tumours in endocrine
related organs EFSA (2005a)
Flusilazole Carc 2 (H351), Rep 1B (H360D), Acute Tox
4 (H302)
Liver (histopathology, tumours), blood (anaemia), bladder (tumours),
testes (tumours), reproductive toxicity (Increased gestation length and
dystocia, associated reduced pup viability and survival),
developmental toxicity
European Commission (2007)
Myclobutanil Rep 2 (H361d), Acute Tox. 4 (H302),
Eye Irrit 2 (H319)
Liver (weight, histopathology), testes (atrophy, oligospermia),
developmental toxicity (altered viability index without maternal
toxicity)
Classiﬁed after Jan 2011;
EFSA (2010b)
Profoxydim Carc 2 (H351), Rep 2 (H361d) Liver (histopathology, tumours), testes (atrophy, tumours),
developmental toxicity (reduced anogenital distance, hypospadias,
undescended testes, testicular atrophy)
Classiﬁed after Jan 2011
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Data evaluation and decision making for the 16 substances orig-
inally pre-selected according to classiﬁcation and labelling (under-
lined in Table 1) was performed by two to three risk assessors
independently. Evaluation and decision making for the randomselection and the organic pesticides was performed by one or
two risk assessors. Decision strategies are presented in Fig. 1 and
Table 4 and also in (Marx-Stoelting et al., 2011). Data were
obtained as described in section 2.2 and basically, all available data
were evaluated. With respect to decision strategies 1 and 2
(Options 1 and 2) adverse effects potentially related to endocrine
Table 2
List of substances randomly selected from annex I of Dir 91/414/EEC. The table shows the classiﬁcation as of July 2013 according to annex VI of Regulation (EU) No 1272/2008 as
well as target organs and adverse effects reported in the respective EU monographs and/or EFSA conclusions.
Substance name Classiﬁcation (human health) Target organs (effects considered for decision on ED) Remarks
Benzoic acid Not classiﬁed Effects on liver kidney and brain at dose levels above 500 mg/kg bw/d in short term
studies; no effects in long term or multigeneration studies
European
Commission
(2003a)
Chlorpyrifos Acute Tox 3 (H301) Nervous system/inhibition of acetyl-cholinesterase; adrenal gland (weight,
histopathology)
EFSA (2011a)
Carbon dioxide Not classiﬁed None European
Commission
(2008)
Clodinafop-p Acute Tox 4 (H302), STOT-RE 2
(H373), Skin sens 1 (H317)
Liver peroxisome proliferation demonstrated in rats and mice. In vitro investigations
with human hepatocytes demonstrated lack of relevance to human risk assessment
EFSA (2005b)
Cypermethrin Acute Tox 4 (H302), STOT-SE 3
(H335)
Neurotoxicity, liver, thyroid effects at high dose levels in published literature European
Commission
(2005b)
Deltamethrin Acute Tox 3 (H331, H301) Nervous system (neurological effects) European
Commission
(2002a)
Dimethenamid-P Not classiﬁed Liver (biochemical and histopathological changes), decreased body weight gain European
Commission
(2003b)
Ethephon Acute Tox 4 (H332, H312) Skin corr
1B (H314)
Inhibition of ChE activity in erythrocytes EFSA (2008e)
Fenpropidin Not yet classiﬁed Local irritation, body weight, liver (hypertrophy), spinal cord demyelination, corneal
opacity
EFSA (2007a)
Famoxadone STOT-RE 2 (H373) Liver (centrilobular hypertrophy, diffuse fatty changes, increased bile pigment and
necrosis); blood (RBC, Heinz bodies, associated haemolysis) (spleen is a secondary target
organ. Eye toxicity (lens effects) was observed in dogs)
(European
Commission
(2002b)
Florasulam Not classiﬁed for human health Liver, kidney (collecting duct hypertrophy, papillary mineralisation, necrosis and
inﬂammation), adrenals (vacuolation, dogs only, high dose effect)
European
Commission
(2002c)
Fluoxastrobin Not classiﬁed Liver (main target organ in dogs, mice and rats, altered AP levels in dogs), Kidney/
urethra/bladder lesions (at high dose in rats; changes in calcium/phosphate metabolism
in rat long term studies)
EFSA (2007b)
Fluroxypyr Not classiﬁed for human health Kidney. No evidence for a carcinogenic or reprotoxic potential EFSA (2011b)
Foramsulfuron Not classiﬁed Unspeciﬁc effects: decreased body weight gain and food consumption European
Commission
(2002d)
Glyphosat Eye dam 1 (H318) Liver (organ weight", clinicial chemistry, histology); salivary glands (organ weight",
histology); stomach mucosa and bladder epithelium (histology); eye (cataracts)
European
Commission
(2002e)
Linuron Rep 1B (H360Df), Carc. 2 (H351),
Acute Tox 4 (H302), STOT RE 2
(H373)
Liver, red blood cells, testes (Leydig cell tumours), adrenal gland (histopathology)
reproductive toxicity (infertility) developmental toxicity (malformations)
European
Commission
(2002f)
Mancozeb Rep 2 (H361d), Skin Sens 1 (H317) Thyroid (inhibition of thyroid peroxidase, histopathology, tumours), developmental
toxicity (malformations at high dose levels, abortions, delayed ossiﬁcation)
European
Commission
(2009)
Metiram Not classiﬁed Thyroid (inhibition of thyroid peroxidase, hyperplasia/hypertrophy), liver (increased
weight), atrophy of hindlimb muscles in rats. No evidence for a carcinogenic or
reprotoxic potential
European
Commission
(2005c)
Pethoxamid Acute Tox 4 (H302), Skin sens 1
(H317)
Rat: liver (induction of drug metabolising enzymes, hypertrophy) and thyroid
(hypertrophy, hyperplasia, tumours⁄). Dog: gastrointestinal tract (stomach: vacuolation,
atrophy of the muscle layer at the highest dose only). Mouse: liver (induction of drug
metabolising enzymes, hypertrophy, tumours⁄), small intestine (swelling, rarefaction,
hypertrophy of villous epithelial cells)
⁄tumours considered to be based on a rodent speciﬁc mechanism
European
Commission
(2006)
Propoxycarbazon Not classiﬁed for human health Decreased body weight gain, increased water intake; irritation of forestomach
epithelium (rats); decreased food consumption and relative heart weights (dog)
European
Commission
(2003e)
Prosulfuron Acute Tox 4 (H302) Liver (hepatocyte hypertrophy), heart (myocardial degeneration), haematopoietic
system (red blood cells decreased), uterus and mammary gland in rats at high dose
levels
European
Commission
(2002g)
Triﬂusulfuron Not yet classiﬁed Body weight, food intake/decrease; liver: increased weight, elevated liver enzymes,
hypertrophy; blood (erythrocytes): regenerative anaemia; Testis/increased incidence of
Leydig cell hyperplasia and adenoma in male rat
EFSA (2008d)
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see whether or not an endocrine mode of action could be plausible.
If this was the case, it was analysed if human relevance should be
assumed or could be excluded based on the present data as sug-
gested by the WHO/IPCS mode of action framework (Boobis
et al., 2008). If this was not the case, different regulatory conclu-
sions were drawn. According to Option 1, the regulatory decision
was based on mode of action and adversity (hazard identiﬁcation)only, taking into account human relevance but not dose levels at
which effects occurred. Option 2 was based on Option 1 but addi-
tional elements of hazard characterisation were taken into
account, including the dose levels at which the effects were
observed and their severity to differentiate between endocrine dis-
ruptors of different levels of regulatory concern (ED1 or ED2).
Option 3 consisted of the classiﬁcation-based interim decision cri-
teria laid down in the plant protection products regulation. While
Table 3
List of substances randomly selected from annex II of Regulation (EC) 834/2007 (i.e. substances approved for use in organic agriculture). The adverse effects and the studies these
were observed in are presented as well as a potential mode of action, the LOAEL and decisions according to Option 1 and Option 2. Mode of action: ED = endocrine mode of action
is plausible; ED? Endocrine mode of action cannot be excluded; ? = mode of action unclear but, considering the pathology of the adverse effects, most likely not endocrine; no
ED = no endocrine mode of action. Effects are summarised in respective EFSA scientiﬁc reports for copper sulphate (EFSA, 2008a), ferric (III) phosphate (EFSA, 2004, 2005c) and
rapeseed oil (RMS Spain, 2007).
Substance name Adverse effects (study) Mode of
action
Decision based on hazard
identiﬁcation (Option 1)
LOAEL
[mg/kg bw/d]
Decision based on hazard
identiﬁcation and
characterisation (Option 2)
Copper sulphate
(EFSA, 2008a)
Liver (histopathology); short-
term, oral, rat and mouse
? No cut-off >16 No cut-off
Kidney (hyaline droplet
nephropathy) short-term, oral,
rat
No ED No cut-off >16 No cut-off
Blood (changes in HGB, red
blood cell and platelet counts)
ED? Consider cut-off >16 No cut-off
Developmental toxicity
(malformations) non-GL dev.
Tox study, ip and iv
administration, mouse and
hamster; effect not observed in
an oral rat study
ED? Consider cut-off?; Severe effect but
unrealistic exposure route (ip, iv)
effect, not observed in an oral rat
study
>30 Severe effect but unrealistic
exposure route (ip, iv), effect not
observed in an oral rat study;
high dose effect; no cut-off
Testis (degeneration); peritoneal
injection of copper
ED Consider cut-off? Severe effect but
unrealistic exposure route, not
observed in oral studies
? Severe effect but unrealistic
exposure route, not observed in
oral studies, no cut-off
Ferric (III)
phosphate
Increased risk of diabetes
mellitus in patients with chronic
iron overload or long term
ingestion of high doses of iron,
epidemiology (EFSA, 2004)
ED Cut-off 160–1200 mg/d Severe effect, however high dose
effects; no cut-off
Liver (haemosiderosis) ? No cut-off 160 – 1200 mg/d No cut-off
Parathyroid (hyperplasia)
(caused by phosphate) (EFSA,
2005c)
ED? Consider cut-off 160 – 1200 mg/d No cut-off
Rapeseed oil (RMS
Spain, 2007)
Body weight changes, long-term,
oral, rat
? No cut-off 20000 ppm No cut-off
Heart (histopathology,
degeneration of cardiac muscle
ﬁbre if oil contained high eruic
acid levels), long-term, oral, rat
? No cut-off 20000 ppm No cut-off
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as carcinogenic category 2 (C2)/reprotoxic category 2 (R2), the
decision on substances classiﬁed only as R2 and causing toxicity
to endocrine organs (maybe ‘‘cut-off’’) would be made based on
expert judgement. Box 1, Fig. 1 and Table 4 summarise the three
options and compare the criteria they used. Adversity in this con-
text has been used as deﬁned by WHO/IPCS (2004). For severity in
the present exercise the following working deﬁnition has proven
helpful: ‘‘A severe effect is an effect which is either graded as severe
in nature or irreversible. Typical irreversible effects comprise (but
are not limited to) tumours, irreversible forms of organ damage,
malformations or infertility’’. In study reports an organ hyperplasia
or structural change might be described as ‘mild’/’slight’, ‘moder-
ate’ or ‘severe’ in accordance with respective guidelines for pathol-
ogists. These descriptions were adopted when judging severity of
effect.
To obtain information on the reproducibility of the respective
evaluations and decisions on endocrine disruptors by the indepen-
dent regulators from our department their ﬁnal conclusions were
compared for each of the three options. Regulators reported results
for each of the substances they evaluated in keywords and in tab-
ular form and a central evaluation table to summarise the results
for each of the three options was compiled. Since only the ﬁrst
set of 16 substances was evaluated independently by two to three
risk assessors, reproducibility has been checked only for this set of
substances.
Additionally, risk assessors were asked to note difﬁculties
occurring during the evaluation process with each of the different
options. This was used to obtain information on applicability,
which was examined for the ﬁrst and the second set of substances
accordingly. If experts disagreed in their conclusions, e. g. ‘‘cut-off’’versus no ‘‘cut-off’’ and no majority for a certain position could be
found, the stricter conclusion, i.e. ‘‘cut-off’’, was chosen for decision
on the substance.
2.4. Exposure calculation
According to annex II, point 3.6.5. of Reg. (EC) No 1107/2009,
approval of substances with endocrine disrupting properties is
not possible unless exposure under realistic conditions of use is
assumed to be negligible (European Council, 2009). Hence it was
important to estimate the expected dietary exposure, in order to
ﬁnd out for how many substances exposure was actually negligi-
ble. Calculation of overall chronic dietary exposure was performed
with EFSA’s pesticide residue intake model (PRIMo) for each of the
16 substances selected based on classiﬁcation and labelling
(Table 1) and thus potentially falling under the preliminary ‘‘cut-
off’’ (EFSA, 2007c), but, due to limitations in time and resources
not for the other substances. The maximum residue level as set
by Reg. 396/2005 was compared to the default residue concentra-
tion of 0.01 mg/kg food, which is deﬁned as negligible by Regula-
tion (EC) 1107/2009 (European Council, 2009). In addition, with
regard to operator exposure, the intended uses supported during
the EU evaluation of the substances were checked to establish
whether or not only applications in closed systems are foreseen
and if consequently the second criterion for negligibility set by
the new EU plant protection products regulation was met.
2.5. Questions addressed
The primary aim of this study was to test three different
approaches of regulatory decision making on pesticides with
Hazard identification Classification-
based 
identification
of substances
Additional
elements of 
hazard 
characterisation
ED 1 ED 2
Cut-off Cut-off Cut-off “May be”
Cut off
Option 1 Option 2 Option 3
C2/R2
R2
Risk 
assessment
Fig. 1. Illustration of key elements in the decision process of each of the three tested options for regulatory decision making. ED: Endocrine disruptor; C2: Carcinogenic
Category 2 according to Regulation (EC) No 1272/2008; R2: Toxic for Reproduction Category 2 according to Regulation (EC) No 1272/2008.
Table 4
Criteria used for decision making within a weight of evidence approach under the two regulatory options published by Marx-Stoelting et al., 2011 as compared to the interim
criteria laid down in Reg. (EC) No 1107/2009. In this context weight of evidence should be understood as suggested by EChA 2010 as ‘a process of considering the strengths and
weaknesses of various pieces of information in reaching and supporting a conclusion concerning a property of the substance’.
Considered criterion BfR Option 1
(based on hazard
identiﬁcation)
BfR Option 2 (based on hazard
identiﬁcation and additional
elements of hazard characterisation)
Option 3 (interim criteria
according to Reg. (EC)
No 1107/2009)
Adverse effect Yes Yes Yes
Endocrine mode of action Yes Yes No
Relevance to humans Yes Yes Yesa
Potency No Yes No
Severity No Yes Yes
Lead effect No No No
Current legal classiﬁcation No No Yes
Consistency (i.e. No of species/tissues concerned) No No No (but contributes to classiﬁcation)
a Questionable.
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teria might have on the approval of substances and also for the
reproducibility and applicability of their criteria. In addition to
the primary aim, the data analysed in this study were also used
to address the questions, which parts of the endocrine systemwere
affected by ED most frequently, which studies were the most sen-
sitive in detection of ED effects and whether or not NOAELs were
observed for substances with ED properties.
3. Results
3.1. Substance set pre-selected based on classiﬁcation and labelling
3.1.1. Flagging of substances
In total 16 substances were pre-selected, based on their classi-
ﬁcation for carcinogenicity and/or reproductive toxicity, as by Jan-
uary 2011. Application of Option 1 (hazard identiﬁcation only,
based on adversity and mode of action) to these 16 substances
resulted in the decision that 15/16 active substances have at least
some endocrine disrupting properties, while 1/16 was considered
not to be an endocrine disruptor. This is not surprising because
the substances were selected based on the interim ‘‘cut-off’’ crite-
ria which are biased towards substances affecting the HPG axis.
The outcome for hazard identiﬁcation did not change when the
Option 2 was applied. With Option 2, it was, however, possible
to further differentiate between the positive substances based onhazard characterisation, taking into account severity of effects
and doses at which effects occur. According to the criteria for pri-
oritisation of endocrine disruptors speciﬁed in the BfR proposal
(Marx-Stoelting et al., 2011), 6 substances were regarded as endo-
crine disruptors of high priority (‘‘ED1’’ category substances) and 9
as endocrine disruptors of lower priority (‘‘ED2’’ category sub-
stances). The third option (equalling the interim ‘‘cut-off’’ criteria)
led to partially conﬂicting results, depending on interpretation of
the interim criteria. See Table 6 for details.3.1.2. Estimated exposure to substances
One out of the 16 substances met the deﬁnition of negligible
exposure to consumers as set by Regulation EC No 1107/2009,
i.e. its MRLs were at or below 0.01 mg/kg food. Consumer dietary
exposure for the 16 substances was calculated according to EFSA
PRIMo (rev.2), based on diets of European consumer groups and
the uses granted in EU member states as of September 2010. Three
of the 16 substances had an exposure of below 10% of the respec-
tive ADI. For the present project, acute dietary exposure to the 16
substances was not estimated. These substances like all others
were not restricted to application in closed systems only and con-
sequently did not meet the criterion of negligible exposure to oper-
ators. Therefore, according to the legeal deﬁnition for negligible
exposure, exposure to none of the 16 substances could be regarded
as negligible.
Table 6
Results of the evaluation according to a preliminary categorisation which must not be used as a basis for deﬁnitive regulatory decisions. If conclusions differed between
regulators, all positions are printed. Results are underlined, if the majority of regulators came to this conclusion. If no majority was found the stricter option was applied for
decision making on non-approval (‘‘cut-off’’). In option 1 ‘‘ED’’ means automatically ‘‘cut-off’’. In option 2 ‘‘ED1’’ equals ‘‘cut-off’’ and in option 3 ‘‘yes’’.
Substance Option 1 Option 2 Option 3
Results for substance set selected based on classiﬁcation (cf. Table 1)
Amitrole ED ED1 Yes
Bromoxynil ED ED2 Yes/No
Chlorotoluron ED ED2 Yes/?
Dimoxystrobin ED/no ED ED2/no ED No/Yes
Epoxiconazole ED ED1 Yes
Fenpropimorph ED ED2/ED1 Yes/No/?
Ioxynil ED ED1 Yes
Isoxaﬂutole ED ED2 Yes/?
Linuron ED ED1 ?/Yes
Mancozeb ED ED2/ED1 ?/Yes
Maneb ED ED2 ?/Yes/No
Metconazol ED ED1 Yes/?
Molinat ED ED1 Yes
Oxadiargyl ED/no ED ED2/no ED No/Yes
Tebuconazole ED ED2/ED1 Yes/?
Tepraloxydim ED ED2 Yes/?/No
Sum ED (‘‘cut-off‘‘) 15/16 (15/16) 15/16 (6/16) 16/16 (16/16)
Similarity in decisions of independent evaluations for ED (‘‘cut-off‘‘) 14/16 (14/16) 14/16 (13/16) 4/16 (5/16)
Results for randomly selected substance set (cf. Table 2)
Benzoic acid No ED No ED No
Chlorpyrifos ED ED2 No
CO2 No ED No ED No
Clodinafop-P No ED No ED No
Cypermethrin ED ED2 No
Deltamethrin No ED No ED No
Dimethenamid-P No ED No ED No
Ethephon No ED No ED No
Famoxadon No ED No ED No
Fenpropidin No ED? No ED? No
Florasulam No ED? No ED? No
Fluoxastrobin No ED No ED No
Fluroxypyr No ED No ED No
Foramsulfuron No ED No ED No
Glyphosat No ED? No ED? No
Linuron (also list 1) ED ED1 Yes/?
Mancozeb (also list 1) ED ED2 Y´es/?
Metiram ED ED2 No
Pethoxamid ED ED2 No
Propoxycarbazon No ED? No ED? No
Prosulfuron No ED? No ED? No
Triﬂusulfuron ED ED2 No
Sum ED (‘‘cut-off‘‘) 7/22 (7/22) 7/22 (1/22) 2/22 (1/22)
Results for substances approved for use in organic agriculture (cf. Table 3)
Copper sulphate ED? ED2? No
Ferric phosphate ED? ED2? No
Rapeseed oil No ED No ED No
Table 5
Endocrine effects observed in vivo caused by 22 randomly selected pesticides and 3 organic pesticides. The most sensitive studies (i.e. in which effects occurred at the lowest dose)
are listed as well as example effects observed in pathology and histopathology. Some substances affected more than one endocrine target organ, hence the number of cases listed
exceeds the number of endocrine disruptors identiﬁed. Overall thyroid and adrenals were affected most often.
Affected endocrine-related endpoint Sensitive studies Example effects Cases detected [ntotal = 25]
Adrenal gland Chronic, short term Weight changes, tumours, hypertrophy,
vacuolisation
4
Endometrium Chronic Hyperplasia 1
Fertility Dev tox, 2-generation Reduced fertility 2
Malformations Dev tox, 2-generation Wolfﬁan duct malformation cleft palate 2
Ovary Chronic Weight changes, tumours, cysts, hypertrophy 2
Pancreas Chronic Pale coloured, diabetes, b-cell degeneration 2
Pituitary Short term Weight changes 1
Prostate Chronic Weight changes 1
Parathyroid Chronic Hyperplasia 1
Testis Chronic, 2-generation Weight changes, altered sperm parameters,
tumours Leydig cell hyperplasia, atrophy
3
Thyroid Chronic Weight changes, tumours, hypertrophy,
hyperplasia
5
Uterus Chronic Weight changes, tumours 2
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3.2.1. Endocrine disrupting properties of substances
Twenty-two randomly selected substances were subjected to
analysis and regulatory decision making on endocrine disrupting
properties using the three different options. Random selection
seemed the most appropriate way to sample substances for the
testing of different sets of criteria in an unbiased way. When
Option 1 (hazard identiﬁcation only, based on mode of action
and adversity) was applied, 7/22 substances (32%) were consid-
ered to have endocrine disrupting properties. This was similar
when the second option (hazard identiﬁcation plus characterisa-
tion taking into account severity of effects and doses at which
effects occur) was applied at the hazard identiﬁcation stage. How-
ever, it was additionally possible via Option 2 to differentiate
between one substance (‘‘ED1’’, 5%) of higher regulatory priority
and 6 substances (‘‘ED2’’, 27%) of lesser priority. When the
classiﬁcation-based Option 3 was applied, 2 substances (10%)
were identiﬁed as candidates for endocrine disruption, with one
substance classiﬁed C2/R1B (5%, direct ‘‘cut-off’’) and one sub-
stance classiﬁed R2 only (5%, may be ‘‘cut-off’’). Detailed results
are presented in Table 6.
3.2.2. Estimated numbers of pesticides falling under ‘‘cut-off’’
When using Option 1 for a regulatory ‘‘cut-off’’, approximately
32% of the substances were affected. Even if the relevance of this
ﬁnding for the entirety of approved pesticide active substances is
unclear because of the limited sample size [nsample = 22,
ntotal = 351], it seems very likely that with this decision strategy
based only on hazard identiﬁcation a large percentage of active
substances (20–40%) would be considered for banning.
When Option 2 was applied, one of the identiﬁed endocrine dis-
ruptors was categorised as ‘‘ED1’’ and thus would be prioritised
according to the BfR proposal. The remaining 6 substances identi-
ﬁed as potential endocrine disruptors showed endocrine disrupting
effects at generally higher dose levels in the toxicity studies. Rather
than being considered for hazard-based banning, the BfR proposal
suggests that they are subjected to a thorough risk assessment pro-
cedure to decide on approval or non-approval.
With Option 3, one substance directly fell under the ‘‘cut-off’’
due to its classiﬁcation as carcinogenic category 2 and toxic for
reproduction category 1B. Another substance, labelled toxic to
reproduction category 2 would ﬁt the criteria for ‘‘may be cut-
off’’, and thus might be considered for hazard-based prioritisation,
depending also on expert judgement concerning toxicity towards
endocrine organs. Overall, for the randomly selected set of 22
active substances, our estimation showed that the interim criteria
set within Reg. (EC) 1107/2009 and the proposed Option 2 ﬂagged
similar numbers of pesticide active substances for consideration of
hazard-based banning ( 5% of substances), while Option 1 clearly
ﬂagged a higher percentage of active substances.
3.3. Substances approved for organic farming
Use of pesticides approved for organic agriculture is often per-
ceived to carry a low potential to negatively affect human health
or the environment. Three of these substances were included in
the present study for purposes of comparison. Adverse effects of
such compounds have been detected by toxicological studies sub-
mitted for regulatory purposes or published in the open literature.
These data are summarised in Table 3, together with the modes or
mechanisms of action suggested for these substances, the respec-
tive NOAELs and LOAELs and the regulatory conclusions resulting
from application of either Option 1 or 2.
Based on Option 1, two of three substances might be regarded
as having endocrine disrupting properties since they were shownto cause some adverse effects in intact organisms that might be
due to an endocrine mechanism of action. The level of evidence
was, however, higher for one of the substances and less convincing
for one of the others because in that case, an inappropriate (paren-
teral) route of exposure was used in eliciting the adverse effects
(see discussion and Tables 3 and 6 for details).
According to Option 2, the substances causing adverse effects
on endocrine organs via a potential endocrine mode of action
would also be considered as endocrine disruptors. However,
due to the fact that all adverse effects were conﬁned to higher
dose levels none of the investigated organic pesticides would
be likely to be regarded as being of high regulatory concern
(‘‘ED1’’). Consequently, according to Option 2, all of these sub-
stances would be evaluated further by thorough risk assessment
procedures.
Since the three example substances are not classiﬁed or labelled
for reproductive toxicity category 2 or carcinogenicity category 2
according to Regulation (EC) No 1272/2008, none of them would
be considered for ‘‘cut-off’’ as endocrine disruptors under the clas-
siﬁcation-based Option 3. When interpreting these results, the very
low sample size must be taken into consideration.3.4. Reproducibility of decisions and ease of application of criteria
The criteria laid down in the three different regulatory options
were applied by two to three regulators independently to the sub-
set of 16 substances that had been pre-selected based on classiﬁca-
tion and labelling (Table 1). Decisions were compared among
regulators to see whether they would come to similar scientiﬁc
evaluations and regulatory conclusions. Additionally, regulators
were asked to record the difﬁculties they had when applying each
of the options to subset 1 and 2. Results on the reproducibility of
the scientiﬁc evaluations and regulatory decisions and on the
applicability (ease of decision making) are presented separately
below.
With Option 1 and 2, the regulators came to similar conclusions
on the identiﬁcation of endocrine disrupting properties of the sub-
stances in 14/16 cases (87.5%). Concerning the regulatory conse-
quence (‘‘cut-off’’, no ‘‘cut-off’’, no decision possible) all
regulators arrived at similar conclusions in 14/16 cases (87.5%)
with Option 1 and to a slightly lesser degree (13/16 cases; 81.3%)
with Option 2. In cases for which regulators came to different
results with Option 2 (3/16, 18.7%), the regulatory conclusions dif-
fered only by one step (‘ED1’ vs. ‘ED2’).
Surprisingly, the classiﬁcation-based Option 3 was the one
where deviations between different regulators were most pro-
nounced. This might be explained by the fact that the interim cri-
teria toxic for reproduction category 2 and having toxic effects on the
endocrine organs as a basis for consideration as having endocrine-
disrupting properties (according to point 3.6.5 of annex 2 of Regu-
lation (EC) 1107/2009) is prone to very different interpretations by
different regulators.
With respect to applicability the main difﬁculties arose from
uncertainties concerning the mode of action (50% of cases with
adverse effects potentially related to ED), the judgement on human
relevance (according to the WHO/IPCS human relevance
framework used in this exercise, the default assumption always
is relevance), and conﬂicting data. Problems in decision making
were noted most often for Option 1, followed by Option 3. Fewer
difﬁculties concerning the applicability in terms of ﬁnal decision
making were noted with Option 2, most likely because here, even
in the presence of uncertainties, the inclusion of additional deci-
sion criteria (elements of hazard characterisation including
potency) supported a higher level of conﬁdence for regulatory
decision making.
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In order to illustrate the application and comparative perfor-
mance of different assessment and decision criteria, we present
two practical examples from this study, one clearly positive sub-
stance and one substance used in organic farming. These examples
also demonstrate the interaction of scientiﬁc evaluation and
regulatory decision making.
3.5.1. Linuron
Linuron has been approved as an herbicide in the EU. It is
known to have anti-androgenic properties and is therefore
included as a positive control in the US EPA endocrine disruptor
screening program (EDSP) or for validation of methods capable of
detecting anti-androgenic properties such as the Hershberger
assay (Moon et al., 2009, 2010). The decision process on linuron
as conducted in the present study is illustrated in Fig. 2. The
analysis was based on the EU monograph (RMS UK, 1996) and
the respective EFSA conclusion (European Commission, 2002f).
Additionally, a literature search was performed and several publi-
cations, especially on the mode of action, were taken into account
for the decision process (Freyberger et al., 2010; Freyberger and
Schladt, 2009; Lambright et al., 2000; McIntyre et al., 2002a,b;
Tinwell et al., 2007; Turner et al., 2003; Vinggaard et al., 1999,
2000).
In the context of data evaluation, a number of adverse effects
potentially related to endocrine disruption were detected, includ-
ing tumours (Leydig cells, ovaries, uterus, endometrium, liver),Fig. 2. Decision logic for the example substance linuron. After evaluation of all data an
analysis of the mechanisms, which might have caused toxicity (green boxes). This mech
mode/mechanism of action in animals. If this mechanism is related to ED, its relevance t
(blue box). In the last step (red boxes) a regulatory decision is made. This could be b
additionally take into account elements of hazard characterisation (Option 2). Option 3 re
the EU regulation. GL: guideline, h: human, r: rat, AR: androgen receptor, yr: year, mo: m
this ﬁgure legend, the reader is referred to the web version of this article.)foetal malformations (Wolfﬁan duct derivatives), reduced fertility
or infertility, target organ effects (testis atrophy, adrenal gland
hypertrophy).
Mechanistic data were evaluated, conﬁrming an anti-andro-
genic mode of action (Freyberger et al., 2010; Kang et al., 2004;
Lambright et al., 2000; Tinwell et al., 2007; Wilson et al., 2009)
and partially excluding other MoA like aromatase inhibition or
estrogenicity (Vinggaard et al., 1999, 2000).
A further parameter addressed in the decision process was
human relevance. Since hormone receptors are quite conserved
among various species and one study showed a higher afﬁnity of
linuron to the human androgen receptor than to the rat androgen
receptor (Lambright et al., 2000) it seems plausible to assume rel-
evance to humans, which would have been the default assumption
according to the WHO/IPCS mode of action framework (Boobis
et al., 2008) in the absence of data anyway. To sum up the results
of the evaluation with respect to hazard identiﬁcation, linuron
would have to be regarded as a substance causing adverse effects
in intact organisms by an endocrine disrupting mode of action with
relevance to humans.
In the last step of the analysis a regulatory decision has to be
made according to one of the three options. According to Option
1, linuron would have to be regarded as an endocrine disruptor
and would consequently fall under the ‘‘cut-off’’. Since linuron pro-
duced a range of severe effects at generally low exposure concen-
trations it also would be considered an endocrine disruptor of high
regulatory concern (‘‘ED1’’) according to Option 2, and would thus
be proposed to be ﬂagged for ‘‘cut-off’’ with Option 2. Similarly,endpoint- based hazard analysis is conducted (grey boxes). This is followed by an
anistic evaluation includes criteria like adversity as well as the establishment of a
o humans will be analysed with the default assumption being relevance to humans
ased on hazard identiﬁcation alone (Option 1). Alternatively, this decision might
presents the classiﬁcation based decision as suggested by the interim criteria set by
onth, d: day, RBC: red blood cells. (For interpretation of the references to colour in
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off’’ criterion for being labelled toxic to reproduction category 1B.
Based on these ﬁndings, it can be concluded that all three sets of
criteria were able to ﬂag linuron as positive.
3.5.2. Ferric phosphate
Ferric phosphate has been approved as a molluscicide in the EU.
It is additionally included in annex II of Regulation (EC) No 834/
2007 for use in organic agriculture. Iron is an essential trace ele-
ment. It is of physiological importance for oxygen transport and
storage and acts as an essential co-factor in many enzymes, espe-
cially those involved in redox reactions. The WHO regards iron
deﬁciency as a serious global health problem, leading to anaemia,
adverse pregnancy outcomes and reduced immune function
(WHO, 2008). However, free iron is highly reactive and needs to
be closely controlled in living cells. Disorders associated with
chronic iron overload in individuals homozygous for hereditary
haemochromatosis include diabetes mellitus. In addition, some
cases have been reported of patients who developed secondary
haemochromatosis, among others with diabetic manifestation,
due to long-term high-dose medical treatment with iron (e. g.
160–1200 mg iron/day for over a decade), although subjects with
a disposition for hereditary haemochromatosis might have
contributed to these cases (reviewed by EFSA, 2004). Further, a
number of epidemiological studies have indicated an association
between haem iron intake from red meat and type II diabetes
mellitus (reviewed by EFSA, 2004). A more recent meta-analysis
concluded that: ‘‘Higher haem iron intake and increased body iron
stores were signiﬁcantly associated with a greater risk of type II
diabetes mellitus.’’ Dietary total iron, non-haem iron, or
supplemental iron intake were not signiﬁcantly associated with
type II diabetes (Bao et al., 2012). Some experimental evidence is
provided by studies involving animal models. For example, Awai
et al. (1979) demonstrated induction of diabetes in animals by par-
enteral administration of ferric nitrilotriacetate as a model of
experimental haemochromatosis. Dietary iron restriction or iron
chelation was shown to protect from diabetes and loss of beta-cell
function in a mouse model for type II diabetes (obese ob/ob lep-/-
mice; Cooksey et al., 2010).
Thus, although the information from epidemiological studies is
partially conﬂicting, it appears plausible that excessive iron intake
or iron overload may be associated with adverse effects on the
endocrine system. Accordingly, both option 1 and option 2 might
identify iron as an endocrine disruptor. Option 2, however, would
tend to categorise iron as ED2, since diabetes has been associated
with excessive iron intake or cases of iron overload.
With respect to the classiﬁcation-based Option 3, neither iron
nor phosphate nor ferric phosphate is classiﬁed for reproductive
toxicity or carcinogenicity. Based on these ﬁndings, it can be con-
cluded that ferric phosphate might be ﬂagged for ‘‘cut-off’’ for
endocrine disruption under Option 1, but not under the Options
2 and 3.
3.6. Effects considered suggestive of endocrine disrupting properties
and sensitivity of studies
As suggested by the BfR criteria (Marx-Stoelting et al., 2011) all
available data were included in the present study and all poten-
tially endocrine-related effects were taken into account. Isolated
effects on organs like liver or kidneys that are not only endocrine
glands but have numerous other functions were not included auto-
matically as endocrine effects, e.g. an increase in liver weight alone
was not regarded as endocrine effect if no other ﬁndings were
reported. However, if that increase in liver weight was accompa-
nied for example by changes in blood hormone levels, a potential
down-stream consequence of an altered metabolic capacity ofthe liver, the effect was taken into account for the evaluation of
endocrine disruptive properties. Table 5 summarises the effects
leading to endocrine disruptor identiﬁcation for the random selec-
tion [n = 22] and the organic pesticides [n = 3]. The ﬁrst set of sub-
stances (classiﬁcation-based selection) was excluded from this
analysis because among substances already classiﬁed for reproduc-
tive toxicology a clear bias for substances affecting the HPG axis
might be expected. The results show that even in this small group
of substances, many tissues besides those with functional relation
to the HPG axis are affected by endocrine mediated activity, espe-
cially the adrenals and the thyroid but also the pancreatic system.
Most interestingly, if adverse effects pointing to an endocrine
mode of action occurred, they were usually seen in several studies
or in several species or tissues and as part of a set of effects all sup-
porting an endocrine-related mode of toxicity. As an example, linu-
ron showed effects on various organs and functions, which is fully
in line with the postulated anti-androgenic MoA. This observation
could have two implications:
(A) As already practiced for carcinogenicity the number of
affected species, sexes and tissues could contribute as an
additional criterion (‘‘consistency’’) for regulatory decision
making on endocrine disruption (see Discussion).
(B) It may be possible to formulate a hypothesis on the mode of
action and to test it for strength, coherence and plausibility
by a thorough investigation of the toxicological data pre-
sented in the regulatory data package, in some cases even
without the need for further mechanistic data. This could
be applicable to some compounds for which extensive
in vivo data are available, such as pesticides and biocides.
In the case of linuron and other substances it was found that the
highest tier study from the OECD conceptual framework for the
testing of endocrine disruptors (OECD, 2002) was not the most sen-
sitive study. The OECD framework makes a distinction between
different levels with the highest tier being multigeneration repro-
ductive toxicity studies (in this speciﬁc case a two-generation
reproductive toxicity study). Table 5 additionally summarises the
study types (e.g. short term or chronic) that were found to be the
most sensitive for detection of endocrine related effects in the data
packages analysed within the present study. With the available
data package some effects are easier to detect by a chronic toxicity
study than by a two-generation reproductive toxicity study and
vice versa.
3.7. No observed adverse effect levels for the evaluated substances
In this survey, reports summarising approximately 300 regula-
tory toxicity studies were evaluated. In only very few of these stud-
ies, no NOAEL was established. However, in virtually all such cases
a follow-up study using lower dose levels was conducted to estab-
lish an NOAEL, e.g. the long-term NOAEL for linuron. In addition,
several studies not showing a NOAEL were identiﬁed from the
literature. However, virtually all of these latter studies were not
conducted to determine a NOAEL but to analyse mechanisms of
toxicity and most of them used only a single effective dose level.
Such studies did not provide information on dose-response rela-
tionship. NOAELs were also found for the endocrine-related effects.
NOAELs in one study were usually conﬁrmed by other studies in
the regulatory data package. The data requirements for pesticides
include at least two to three studies on short-term toxicity in dif-
ferent species, studies on chronic toxicity and carcinogenicity (usu-
ally in rats and mice), studies on teratogenicity in two different
species (usually rats and rabbits), a study on reproductive toxicity
(generally a 2-generation study in the rat); all of them with at least
three dose levels and a control group so that the complete package
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the studies.4. Discussion
4.1. Overall comparison of different sets of criteria
Since no gold standard for identiﬁcation of substances with ED
properties exists, a formal validation of any suggested set of crite-
ria is not possible. However, application of the three options for cri-
teria to a random selection of pesticides provides a rough estimate
of an outcome regarding implementation in the context of a more
extensive set of substances. Evaluation of a subset of substances
selected based on classiﬁcation and labelling by different regula-
tors independently yielded an impression on reproducibility. In
addition, the difﬁculties encountered with the application of the
criteria for regulatory decision making could be compared for the
three options applied to two subsets of substances. In conclusion,
none of the sets of criteria could be considered perfect. Option 1
(hazard identiﬁcation only) was associated with a high level of
sensitivity (i.e. number of substances ﬂagged for regulatory
‘‘cut-off’’ was high), and reproducibility of results was good.
Problems generally associated with hazard identiﬁcation included
difﬁculties with mode of action or human relevance assessment.
Option 2 (hazard identiﬁcation plus characterisation) scored high
on sensitivity for hazard identiﬁcation, while it enabled prioritisa-
tion of substances to be regarded as of lower or higher concern. In
addition, reproducibility was comparable to Option 1. Applicability
of Option 2 in terms of facilitating decision making was, however,
regarded as better due to the integration of elements of hazard
characterisation.
When applied within a random selection of substances, Option
3 (only consideration of substance classiﬁcation) showed low sen-
sitivity, presumably due to a focus on substances with reproduc-
tive toxicity. Application of Option 3 regarding the precisely
deﬁned ‘‘cut-off’’ criteria (classiﬁcation as carcinogenic category 2
and toxic for reproduction category 2) can be regarded as easy
since only the classiﬁcation status or requirement for classiﬁcation
of the substance had to be checked to come to a conclusion. The
other criteria within Option 3 (toxic for reproduction category 2
and toxic to endocrine organs), may be ‘‘cut-off’’, leave more room
for interpretation and expert judgement. Accordingly, it was often
difﬁcult to come to a regulatory conclusion based on the may be
‘‘cut-off’’ criteria, and reproducibility was low.4.2. Problems associated with different options for regulatory decision
making
To examine the likelihood that substances should be ﬂagged for
endocrine disrupting properties and the reliability of such an iden-
tiﬁcation, the present study tested different options for regulatory
decision making. Several problems were identiﬁed as being associ-
ated with some of these different options in terms of sensitivity,
reproducibility and applicability. Option 1 (taking into account ele-
ments of hazard identiﬁcation only), while very sensitive, was
prone to ﬂag a high number of substances for hazard-based ban-
ning as endocrine disruptors. Option 3 was shown to have a limited
reproducibility if applied by different regulators concerning the
interpretation of the ‘‘may be’’ criteria and was also shown to be
less sensitive for a random set of substances. In this context it
should be noted that some substances showing tumours in endo-
crine organs are classiﬁed as carcinogenic category 2 but would
be missed by Option 3. Some examples are listed in Table 1.
Reproducibility appeared similar for Option 1 and Option 2 if
these options were applied to the set of 16 pre-selected substancesbased on classiﬁcation and labelling. This is not surprising, as this
pre-selection is clearly biased for substances affecting the HPG
axis, hence resulting in a high number of easily identiﬁable sub-
stances with endocrine disrupting properties. For a randomly-
selected group of substances, less problems in decision making
(as indicated by a better applicability) and a better reproducibility
would be expected for Option 2, as more criteria are taken into
account, supporting a higher conﬁdence in decisions. Overall,
Option 2 (taking into account hazard identiﬁcation plus additional
elements of hazard characterisation) enabled to differentiate
between substances of various potencies and thus to prioritise
for further regulatory measures.
4.3. Additional elements of hazard characterisation
Since a hazard-based approach for non-approval of substances
with certain properties is taken by recent European regulations, it
would be consistent to consider both, elements of hazard
identiﬁcation and hazard characterisation, including potency
and severity of effects. Potency has been used in regulatory haz-
ard assessment since the 1960s and has been implemented in
internationally harmonised regulations for chemical hazard
assessment (European Council, 1967). It is a critical criterion for
determination of acute toxicity and (besides severity of effects)
also for speciﬁc target organ toxicity after repeated dosing
(European Council, 2008). Potency relates to the dose levels at
which certain effects occur. Potency has long been discussed as
a potential criterion for evaluation of EDs (e.g. Borgert et al.,
2012; Sharpe, 2010). Application of a weight of evidence decision
matrix has been suggested for the toxicological assessment of EDs
by a EU report (Kortenkamp et al., 2012). Overall, it seems feasi-
ble to include potency when making regulatory decisions on
endocrine disruptors in combination with other elements of haz-
ard characterisation, such as severity, within such a weight of evi-
dence matrix. Option 2 according to the BfR criteria suggests that
besides the dose that is necessary to induce adverse effects also
the severity of effects should be taken into account when a regu-
latory decision on substances with potential endocrine disrupting
properties is required. This criterion has been demonstrated to be
useful in the present exercise.
The consistency, e.g. number of species, sexes and animals
affected as well as the number of studies or tissues showing posi-
tive results, might serve as an additional criterion to consolidate
concern regarding a substance, i.e. a substance causing testis atro-
phy, Leydig cell hyperplasia and tumours in mice and rats at low
dose levels might be associated with a higher level of concern than
a substance causing only a minimal effect in one study. Thus, con-
sistency could contribute as an additional element of evaluation
within a weight of evidence approach.
4.4. Windows of susceptibility and data requirements
In keeping with the basic principles of toxicology, a recent eval-
uation of data on reproductive toxicants indicated that both the
dose and the window of exposure determine the outcome
(Piersma et al., 2011). Accordingly, if a substance causes critical
adverse effects within a window of susceptibility, this still requires
a dose above a certain level (Piersma et al., 2011). In the present
evaluation, for the evaluated substances showing endocrine dis-
ruptive or developmental toxic properties, dose responses were
reported for these adverse effects that yielded no observed adverse
effect levels under the conditions of the available studies. The dose
causing developmental effects might, however, be lower than the
dose causing maternal toxicity. Hence the effects induced during
critical windows of development must be analysed in addition to
toxic effects observed in short- or long-term toxicity studies. For
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datory requirement for more than two decades. Directive No 91/
414/EC and Regulation (EC) No 1107/2009 stipulate that at least
two studies on developmental toxicity in different species are
conducted as well as at least one multigeneration reproductive
toxicity study. In these studies animals are exposed in utero during
critical windows of susceptibility.
The quality of data that is used for regulatory decision making is
another ﬁeld of discussion (Myers et al., 2009). Quality differences
that impact the informative value of data for regulatory purposes
are most obvious in the area of documentation and experimental
design (use of relevant routes of exposure, group size). While it
is not regarded as an important parameter, whether the experi-
mental work was conducted in an industry laboratory or a univer-
sity research environment, a comprehensive documentation and
presentation of the important parts of an experimental work is
indispensable if this should contribute to a regulatory evaluation.
For example, a publication that does not allow to clearly distin-
guish whether the active substance or a plant protection product
containing it was used in the experiments, has low value for the
purpose of regulating the active substance. In this context, recent
progress towards the development of guidelines for the reporting
of non-standard tests has been made (Beronius et al., 2014;
Kilkenny et al., 2010). Non-standard data may well be considered
for regulatory risk assessment, especially for closing of potential
data gaps on the mode or mechanism of action of a speciﬁc
substance, which is regarded highly important in the context of
endocrine disruption.
Furthermore, studies using appropriate routes of exposure have
to be ascribed a higher regulatory value than studies with less rel-
evant exposure routes. What will be considered appropriate
depends on the protection goal and the realistic route of exposure.
For the evaluation of the risk due to dietary exposure, oral studies
are of highest relevance. However, operators spraying pesticides or
biocides may not be appropriately protected when only oral stud-
ies are considered so that studies with dermal and inhalative
routes of exposure might become preferable. Other routes of expo-
sure (i.v., i.p.) may be considered for understanding a mechanism
of toxicity but are otherwise of limited value for classiﬁcation
and labelling or derivation of reference values for pesticides. The
necessity to apply the same restrictions to the evaluation of endo-
crine disrupting properties can be illustrated with copper sulphate.
Copper compounds are approved as fungicides and are also used in
organic agriculture. Studies are available in which copper was
applied orally or dermally, i.e. via the relevant and realistic
exposure routes under the proposed conditions of use showing
no testicular toxicity. However, intraperitoneal injections of copper
caused testis atrophy (Chattopadhyay et al., 2005). Testicular atro-
phy is a severe effect and indicative of a potentially endocrine-
related mode of toxicity. Findings from studies using non-standard
routes may provide useful information but should be considered
with caution. A decision based on such results for any kind of endo-
crine disruptors should be taken case by case.
4.5. Considering modes of action
For nearly all substances analysed in this exercise, some adverse
effects have been observed. While the detection of toxic effects is
favoured by the design of regulatory studies, the identiﬁcation of
a mode/mechanism of action remains difﬁcult, since mechanistic
data are lacking for most substances. Therefore, it is unclear in
many cases, whether an adverse effect is mediated by endocrine
activity. Since mode/mechanism of action is central to decisions
on potential endocrine disrupting properties, a pragmatic way to
evaluate mode/mechanism of action based on limited data was
used in the present study to come to conclusive decisions.An important point is the level of evidence that should be
regarded necessary to trigger the assumption of an endocrine
mode of action. One option to address this issue would be to use
endocrine disruption as a mechanistic default assumption as sug-
gested in a previous publication (Marx-Stoelting et al., 2011). A
second option would be to assign endocrine disrupting properties
only if a respective mode/mechanism of action was proven. As an
intermediate way between these extreme options we decided to
assume endocrine disrupting properties for the purpose of this
exercise if a respective mode of action seemed plausible as pro-
posed previously (BfR and CRD, 2011), for example if glands were
directly affected or a combination of observations suggested an
endocrine mode of action (e.g. liver effects and changes in blood
hormone levels).
Results of this study clearly show that substances may not only
affect target organs related to the HPG axis but also other parts of
the endocrine system. If regulating endocrine disruptors is taken
seriously this needs to be addressed by increased efforts to develop
and validate tests for other subsystems like the hypothalamic-
pituitary-thyroid- or the hypothalamic-pituitary-adrenal-axis, the
pancreatic system, or the hormonal regulation of metabolic homeo-
stasis and cardiovascular parameters.
5. Conclusion
Overall, the exercise described in this paper demonstrates that
the interim criteria do not seem sufﬁcient to regulate ED but that
a combination of criteria for hazard identiﬁcation with additional
criteria of hazard characterisation (such as severity and potency)
allows prioritising and differentiating between pesticides for a haz-
ard-based regulation. Hence, it is considered necessary to integrate
such elements into a decision matrix to be used within a weight of
evidence approach for the toxicological categorisation of relevant
endocrine disruptors. Moreover, the necessity to consider all parts
of the endocrine system for regulatory decision making on endo-
crine disruption is highlighted. However, to obtain a better under-
standing of the potential impact, a larger number of substances,
preferably randomly selected, would have to be analysed as pro-
posed in the 2014 roadmap for deﬁning criteria for identifying
endocrine disruptors by the European Commission (European
Commission 2014).
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